Any current/future capex/capital investment/strategic investment?

Dabur has invested in an aseptic line for Real's coconut water segment to switch from Tetra Pak to PET bottles, addressing market share loss to new players like Storia. This capex is expected to correct market share issues in the upcoming season (Page 15). There is ongoing investment behind brands with increased A&P expenditure (16% rise in Q1), including digital spends accounting for over 30% of media spends, indicating strategic investment in marketing (Page 4). Dabur is investing ahead of the curve in media to support growth in regions like North India, with a focus on demand generation act

Future growth expectations in sales/revenue/volumes?

International business shows strong growth (18.4% constant currency), expected to improve as currency devaluation impact lessens by Q3 2024. Domestic volume growth is improving sequentially, from 3%-4% to 5.2% in Q1, with optimism for further growth driven by rural recovery and monsoon benefits. Health Supplements expected to perform better in coming seasons, especially Chyawanprash with anticipated severe winter due to La Nina. Quick commerce and e-commerce channels growing rapidly (e.g., 70% growth in quick commerce), increasingly contributing to overall revenue. Foods segment growing strong

Future growth expectations in earnings/operating earnings/profits/EPS?

Gross margin improved by 120 bps, with 80% reinvested into media; operating margin expected to improve but extent uncertain. Deflationary environment expected to persist in Q2; inflation may return in Q3/Q4, requiring monitoring of margins. Media spend to increase, targeting brand investment; India media spends currently at 8% of topline with plans to inch higher. Volume growth expected to pick up sequentially, driven by rural demand recovery; price growth to remain muted (~2%). International business growth strong in constant currency (18.4%), but currency devaluation pressures earnin

Dabur IndiaQ1 FY25Personal Products

Dabur India Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹374P/E: 34.5Market Cap: ₹68.4K CrSector: Personal Products

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

International business shows strong growth (18.4% constant currency), expected to improve as currency devaluation impact lessens by Q3 2024.
Domestic volume growth is improving sequentially, from 3%-4% to 5.2% in Q1, with optimism for further growth driven by rural recovery and monsoon benefits.
Health Supplements expected to perform better in coming seasons, especially Chyawanprash with anticipated severe winter due to La Nina.
Quick commerce and e-commerce channels growing rapidly (e.g., 70% growth in quick commerce), increasingly contributing to overall revenue.
Foods segment growing strongly (21%), Badshah brand growing at 15%.
Oral Care segment growth is robust (~11-13%), with potential for further premium product launches.
Expectation that volumes will continue increasing, though price increases remain limited. Overall growth to improve sequentially in next quarters.

Margin guidance

Category 2

Gross margin improved by 120 bps, with 80% reinvested into media; operating margin expected to improve but extent uncertain.
Deflationary environment expected to persist in Q2; inflation may return in Q3/Q4, requiring monitoring of margins.
Media spend to increase, targeting brand investment; India media spends currently at 8% of topline with plans to inch higher.
Volume growth expected to pick up sequentially, driven by rural demand recovery; price growth to remain muted (~2%).
International business growth strong in constant currency (18.4%), but currency devaluation pressures earnings in INR terms; expected to ease after 1-2 quarters starting Q3.
Health supplements expected to improve with seasonal tailwinds; Chyawanprash growth anticipated to rebound with severe winters.
Operating profit and PAT grew by 8.3% and 7.8% respectively in Q1; continued profitable growth expected given ongoing investments and market expansion.

See what Dabur India management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity for Dabur India Limited. Specifically: - No discussion or announcement related to raising funds via debt. - No mention of issuing equity or any related capital raising activity. - The focus of the call was on operational performance, growth strategies, and market updates. - There were mentions of investing behind brands and media but funded through existing margins and cash flows. - No indication of external funding or capital market activity discussed. Hence, based on the available transcript from the Q1 FY25 results call, there are no disclosed plans for new fundraising through debt or equity at this time.

Order book

The transcript does not provide explicit details on Dabur India Limited's current or expected order book or pending orders. However, relevant insights related to business outlook and growth are: - International business faced supply chain constraints leading to delayed orders, especially in Badshah's international segment, which is expected to correct in the next quarter, potentially improving order fulfillment. - Distribution expansion added 50,000 outlets in direct reach indicating growing demand and channel presence. - Strong demand growth in segments like Oral Care (13% secondary sales growth) suggests ongoing order flow. - Positive rural recovery and improving channel collections imply healthier inventory restocking and order inflows. - Currency devaluation impacts international INR growth but constant currency growth remains strong, supporting future orders. - No concrete order book numbers or pending order details were shared. Thus, while specific order book figures are not disclosed, operational commentary points to robust demand and improving supply chain dynamics.

See what Dabur India management said on order book — free account, 30 seconds.

Capex plans

Yes

Dabur has invested in an aseptic line for Real's coconut water segment to switch from Tetra Pak to PET bottles, addressing market share loss to new players like Storia. This capex is expected to correct market share issues in the upcoming season (Page 15).
There is ongoing investment behind brands with increased A&P expenditure (16% rise in Q1), including digital spends accounting for over 30% of media spends, indicating strategic investment in marketing (Page 4).
Dabur is investing ahead of the curve in media to support growth in regions like North India, with a focus on demand generation activities at INR 10 and INR 20 price points (Page 19).
No specific large-scale new capex projects besides the aseptic line are mentioned in the transcript.
Media and brand investment plans will partly consume the gross margin improvement, signalling continued strategic brand investments going forward (Page 18-19).

Track Dabur India — get its next earnings analysis in your feed

How does Dabur India rank vs peers in Personal Products?

Pro feature

ThisDabur India

Rev 4Mar 2

See where Dabur India sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Dabur India rank in Personal Products?

Compare Dabur India against every Personal Products company (Q1 FY25) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

What Dabur India's management said in earlier quarters

Others in Personal Products this season

Anondita Medicare Ltd (Q4 FY26)
Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year. Key concall takeaways from Anondita Medicare…
Cupid Ltd (Q4 FY24)
6,289 Lakhs, up 57.04% QoQ and 51.59% YoY from Rs. Key concall takeaways from Cupid Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
Cupid Ltd (Q1 FY25)
Total Income (₹ in Lakhs): . Key concall takeaways from Cupid Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
Cupid Ltd (Q4 FY25)
125 crores by FY26, indicating +150% growth (Page 29, 18). Key concall takeaways from Cupid Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Godrej Consumer vs Colgate-Palmoliv vs Cupid Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →